附錄99.1
option care health宣布截至2024年9月30日的第三季度財務業績。
2024年10月30日，伊利諾州班諾克本。 option care health公司（下稱“公司”或“option care health”）（納斯達克股票代碼：OPCH）是全國最大的獨立家庭和其他場所輸液服務提供商，今天宣布截至2024年9月30日結束的第三季度財務業績。
2024年第三季財務業績及亮點
•2023年第三季度淨營業收入為$127850萬，較$109300萬增長17.0%。
•毛利潤為25670萬美元，佔凈營業收入的20.1%，較2023年第三季的25430萬美元，佔營業收入的23.3%，增長1.0%。
•凈利潤為$5390萬，每股摊薄收益為$0.31，較2023年第三季度的凈利潤$5630萬，每股摊薄收益$0.31下降了4.3%。
•調整後的凈利潤為7070萬美元，調整後稀釋每股收益為0.41美元，相較於2023年第三季的調整後凈利潤7310萬美元或每股0.40美元下降了3.2%。
•調整後的EBITDA達到11560萬美元，較去年同期增長5.3%。 $109.8 2023年第三季的收入達到百萬美元。
•營運現金流為16040萬美元，比2023年第三季的6100萬美元增加。
•2024年第三季末，現金及現金等價物結餘為$48300萬。
•2024年第三季度回購了約4190萬美元的股票
約翰C.拉德馬赫（John C. Rademacher），總裁兼首席執行官，評論說：“再次，option care health團隊在第三季度以及整個2024年面臨多個獨特挑戰的情況下，繼續表現出色，專注於為我們的病人提供非凡的護理。我對我們的團隊如何應對自然災害和恢復工作，以及強勁的第三季度財務結果感到自豪。團隊仍然堅韌不拔，並專注於履行我們在2024年承諾，為病人提供一致高質量的護理，並對轉診來源提供可靠的合作夥伴關係。”
Option Care Health宣布，由於颶風海倫的余波，其供應鏈與靜脈輸液袋生產有關的混亂，繼續影響其支持現有和新患者的能力，主要是在急性治療組合中。公司會密切監察情況，與製造商和分銷商合作，以確保現有的庫存。根據目前狀況，公司預期該混亂將對第四季度的財務結果產生負面影響，已納入其2024年更新的指引。目前，Option Care Health無法具體預期供應鏈混亂對其結果的最終解決時間。
2024年全年財務預測更新
對於2024年整年，option care health現在預計將產生:
•營業收入介於49億至49.5億美元。
•調整後的EBITDA介於4.38億至4.43億美元之間
•營運現金流至少3億美元，與先前的指引一致
•26%至28%的有效稅率，與先前的指引一致
•淨利息費約為5500萬至6000萬美元，與先前的指引一致
看漲會議通話
Option Care Health將於今天早上8:30 a.m. Et舉行一次會議來討論該公司2024年第三季度的財務結果。可以通過即將在https://investors.optioncarehealth.com線上提供的現場音頻網絡網絡網絡收聽會議。在通話結束後不久，可以通過現場回播網絡網絡網絡在同一網頁鏈結上隨選收聽該通話的重播，將持續提供約90天。
關於option care health
option care health是全國最大的獨立提供家庭和另類場所輸液服務的供應商。擁有包括4500名以上臨床醫師在內的7500名團隊成員，我們以同理心的態度努力提升對於所有50個州的急性和慢性患者的護理標準。通過我們的臨床領導力，專業知識和國家規模，option care health正在重新想像患者、客戶和團隊成員的輸液護理體驗。欲了解更多資訊，請造訪我們的網站： OptionCareHealth.com.
投資者聯絡方式
| 邁克·夏皮羅 | ||
| 財務長 | ||
| T: (312) 940-2538 | ||
| mike.shapiro@optioncare.com | ||
前瞻性聲明－安全港
本新聞稿可能含有根據美國《私人證券訴訟改革法》1995年安全港條款所指的“前瞻性陳述”。前瞻性陳述可通過如下詞語辨識：“預期”、“打算”、“計劃”、“相信”、“項目”、“估計”、“期待”、“可能”、“應該”、“將”等，並類似地提到未來時段。前瞻性陳述的例子包括，但不限於，我們可能對未來收入、未來盈利、監管發展、市場發展、新產品和增長策略、整合活動以及上述任何事項對我們未來營運結果或財務狀況的影響發表的聲明。
前瞻性聲明既非歷史事實，亦非對未來表現的保證。相反，它們僅基於我們目前對業務未來、未來計劃和策略、預測、預期事件和趨勢、經濟狀況以及其他未來條件的信念、期望和假設。由於前瞻性聲明涉及未來，因此它們面臨固有的不確定性、風險和環境變化，這些變化可能難以預測，其中許多是我們無法控制的。我們的實際結果和財務狀況可能與前瞻性聲明中指示的結果有實質不同。可能導致我們的實際結果和財務狀況與前瞻性聲明中指示的結果有實質不同的重要因素包括但不限於以下:與我們業務模式相關的法律法規變化；市場條件變化和對我們服務和產品的接受程度；懸而未決以及將來發生的訴訟；潛在的保險未涵蓋索賠責任；以及與管理醫療機構和其他非政府第三方支付者的關係喪失。有關可能影響我們實際結果的風險因素的詳細討論，請參閱我們根據證券交易委員會提交的檔案中指定的風險因素。
本新聞稿中我們所作的任何前瞻性陳述，僅基於我們目前掌握的信息，並僅代表其發表之日起的情況。我們不承擔公開更新任何前瞻性陳述的義務，無論是書面還是口頭，可能會不時因新信息、未來發展或其他原因而進行發表。
使用非美國通用會計原則財務指標的注意事項
除了根據普遍接受的會計原則（GAAP）報告財務信息外，公司還報告了調整後的凈利潤、調整後的EBITDA和調整後的每股收益（"調整後的EPS"），這些均為非GAAP財務指標。這些調整後的指標並非是根據GAAP下的財務表現衡量，不應僅作為凈利潤、每股收益或任何其他按照GAAP編制的績效指標的替代品或替代品，也不應僅作為營運活動現金流或公司流動性的替代品或替代品。此外，公司對調整後的凈利潤、調整後的EBITDA和調整後的EPS的定義可能與其他公司報告的同標題非GAAP財務指標不可比。由公司定義：(i)調整後的凈利潤表示無形資產攤銷費用、股票報酬費用和重組、收購、整合及其他開支的稅後調整前凈利潤(ii)調整後的EBITDA表示淨利潤前的淨利息費用、所得稅費用、折舊及攤銷、股票報酬費用、債務消滅損失及重組、收購、整合等開支(iii)調整後的每股收益表示調整後的凈利潤除以加權平均流通股數，按稀釋計算。作為重組、收購、整合及其他開支的一部分，公司可能會發生重大費用，例如據實值列示某些長期資產、暫時性多餘開支、專業費用、某些訴訟費用和有關已收購業務的備用金、潛在的留任和遣散成本，以及對某些合同義務的潛在加速支付或終止成本。管理層認為這些調整後的指標提供了關於Option Care Health業務運作表現的有用補充信息，並促進與公司歷史營運結果的比較。由於對於具體對帳項目的不確定性和可能的變動性，管理層認為未能將調整後EBITDA引導至淨利潤，因此未創建此對帳。每項調整數據與最相應GAAP財務數據的全面對帳下列所示。
Schedule 1
OPTION CARE HEALTH, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS)(UNAUDITED)
| September 30, 2024 | December 31, 2023 | ||||||||||
| ASSETS | |||||||||||
| CURRENT ASSETS: | |||||||||||
| Cash and cash equivalents | $ | 483,026 | $ | 343,849 | |||||||
| Accounts receivable, net | 428,951 | 377,658 | |||||||||
| Inventories | 310,599 | 274,004 | |||||||||
| Prepaid expenses and other current assets | 98,798 | 98,744 | |||||||||
| Total current assets | 1,321,374 | 1,094,255 | |||||||||
| NONCURRENT ASSETS: | |||||||||||
| Property and equipment, net | 125,911 | 120,630 | |||||||||
| Intangible assets, net | 17,768 | 20,092 | |||||||||
| Referral sources, net | 291,839 | 315,304 | |||||||||
| Goodwill | 1,540,246 | 1,540,246 | |||||||||
| Other noncurrent assets | 130,589 | 126,508 | |||||||||
| Total noncurrent assets | 2,106,353 | 2,122,780 | |||||||||
| TOTAL ASSETS | $ | 3,427,727 | $ | 3,217,035 | |||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||||||
| CURRENT LIABILITIES: | |||||||||||
| Accounts payable | $ | 591,971 | $ | 426,513 | |||||||
| Other current liabilities | 171,253 | 191,796 | |||||||||
| Total current liabilities | 763,224 | 618,309 | |||||||||
| NONCURRENT LIABILITIES: | |||||||||||
| Long-term debt, net of discount, deferred financing costs and current portion | 1,105,106 | 1,056,650 | |||||||||
| Other noncurrent liabilities | 133,166 | 120,404 | |||||||||
| Total noncurrent liabilities | 1,238,272 | 1,177,054 | |||||||||
| Total liabilities | 2,001,496 | 1,795,363 | |||||||||
| STOCKHOLDERS’ EQUITY | 1,426,231 | 1,421,672 | |||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 3,427,727 | $ | 3,217,035 | |||||||
Schedule 2
OPTION CARE HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)(UNAUDITED)
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||
| NET REVENUE | $ | 1,278,546 | $ | 1,093,014 | $ | 3,651,784 | $ | 3,177,934 | |||||||||||||||
| COST OF REVENUE | 1,021,797 | 838,748 | 2,907,170 | 2,443,834 | |||||||||||||||||||
| GROSS PROFIT | 256,749 | 254,266 | 744,614 | 734,100 | |||||||||||||||||||
| OPERATING COSTS AND EXPENSES: | |||||||||||||||||||||||
| Selling, general and administrative expenses | 156,999 | 158,214 | 465,524 | 459,644 | |||||||||||||||||||
| Depreciation and amortization expense | 14,659 | 15,005 | 44,294 | 44,417 | |||||||||||||||||||
| Total operating expenses | 171,658 | 173,219 | 509,818 | 504,061 | |||||||||||||||||||
| OPERATING INCOME | 85,091 | 81,047 | 234,796 | 230,039 | |||||||||||||||||||
| OTHER INCOME (EXPENSE): | |||||||||||||||||||||||
| Interest expense, net | (12,345) | (11,786) | (38,150) | (38,816) | |||||||||||||||||||
| Other, net | 808 | 824 | 5,904 | 88,594 | |||||||||||||||||||
| Total other (expense) income | (11,537) | (10,962) | (32,246) | 49,778 | |||||||||||||||||||
| INCOME BEFORE INCOME TAXES | 73,554 | 70,085 | 202,550 | 279,817 | |||||||||||||||||||
| INCOME TAX EXPENSE | 19,698 | 13,783 | 50,860 | 69,904 | |||||||||||||||||||
| NET INCOME | $ | 53,856 | $ | 56,302 | $ | 151,690 | $ | 209,913 | |||||||||||||||
| Earnings per share, basic | $ | 0.32 | $ | 0.31 | $ | 0.88 | $ | 1.17 | |||||||||||||||
| Earnings per share, diluted | $ | 0.31 | $ | 0.31 | $ | 0.87 | $ | 1.16 | |||||||||||||||
| Weighted average common shares outstanding, basic | 170,636 | 178,826 | 172,490 | 179,956 | |||||||||||||||||||
| Weighted average common shares outstanding, diluted | 171,941 | 180,528 | 173,848 | 181,286 | |||||||||||||||||||
Schedule 3
OPTION CARE HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(IN THOUSANDS)(UNAUDITED)
| Nine Months Ended September 30, | |||||||||||
| 2024 | 2023 | ||||||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | |||||||||||
| Net income | $ | 151,690 | $ | 209,913 | |||||||
| Adjustments to reconcile net income to net cash provided by operations: | |||||||||||
| Depreciation and amortization expense | 46,029 | 46,423 | |||||||||
| Other non-cash adjustments | 54,926 | 54,259 | |||||||||
| Changes in operating assets and liabilities: | |||||||||||
| Accounts receivable, net | (51,293) | (5,075) | |||||||||
| Inventories | (36,595) | (28,362) | |||||||||
| Accounts payable | 164,754 | 50,726 | |||||||||
| Accrued compensation and employee benefits | (31,673) | 4,197 | |||||||||
| Prepaid expenses and other current assets | (3,175) | 3,197 | |||||||||
| Other | (7,393) | (14,952) | |||||||||
| Net cash provided by operating activities | 287,270 | 320,326 | |||||||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | |||||||||||
| Acquisition of property and equipment | (25,266) | (21,981) | |||||||||
| Business acquisitions, net of cash acquired | — | (12,855) | |||||||||
| Other investing activities | — | (5,889) | |||||||||
| Net cash used in investing activities | (25,266) | (40,725) | |||||||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | |||||||||||
| Purchase of company stock | (160,122) | (175,108) | |||||||||
| Proceeds from issuance of debt | 49,959 | — | |||||||||
| Other financing cash flows | (12,664) | (12,190) | |||||||||
| Net cash used in financing activities | (122,827) | (187,298) | |||||||||
| NET INCREASE IN CASH AND CASH EQUIVALENTS | 139,177 | 92,303 | |||||||||
| Cash and cash equivalents - beginning of the period | 343,849 | 294,186 | |||||||||
| CASH AND CASH EQUIVALENTS - END OF PERIOD | $ | 483,026 | $ | 386,489 | |||||||
Schedule 4
OPTION CARE HEALTH, INC.
QUARTERLY RECONCILIATION BETWEEN GAAP AND NON-GAAP MEASURES
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)(UNAUDITED)
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||
| Net income | $ | 53,856 | $ | 56,302 | $ | 151,690 | $ | 209,913 | |||||||||||||||
| Interest expense, net | 12,345 | 11,786 | 38,150 | 38,816 | |||||||||||||||||||
| Income tax expense | 19,698 | 13,783 | 50,860 | 69,904 | |||||||||||||||||||
| Depreciation and amortization expense | 15,227 | 15,622 | 46,029 | 46,423 | |||||||||||||||||||
| EBITDA | 101,126 | 97,493 | 286,729 | 365,056 | |||||||||||||||||||
| EBITDA adjustments | |||||||||||||||||||||||
| Stock-based incentive compensation | 10,407 | 9,235 | 27,620 | 22,908 | |||||||||||||||||||
| Loss on extinguishment of debt | — | — | 377 | — | |||||||||||||||||||
| Restructuring, acquisition, integration and other (1) | 4,050 | 3,029 | 7,504 | (74,383) | |||||||||||||||||||
| Adjusted EBITDA | $ | 115,583 | $ | 109,757 | $ | 322,230 | $ | 313,581 | |||||||||||||||
| Net income | $ | 53,856 | $ | 56,302 | $ | 151,690 | $ | 209,913 | |||||||||||||||
| Intangible asset amortization expense | 8,596 | 8,641 | 25,809 | 25,752 | |||||||||||||||||||
| Stock-based incentive compensation | 10,407 | 9,235 | 27,620 | 22,908 | |||||||||||||||||||
| Restructuring, acquisition, integration and other (1) | 4,050 | 3,029 | 7,504 | (74,383) | |||||||||||||||||||
| Total pre-tax adjustments | 23,053 | 20,905 | 60,933 | (25,723) | |||||||||||||||||||
| Tax adjustments (2) | (6,178) | (4,118) | (15,294) | 6,431 | |||||||||||||||||||
| Adjusted net income | $ | 70,731 | $ | 73,089 | $ | 197,329 | $ | 190,621 | |||||||||||||||
| Earnings per share, diluted | $ | 0.31 | $ | 0.31 | $ | 0.87 | $ | 1.16 | |||||||||||||||
| Adjusted earnings per share, diluted | $ | 0.41 | $ | 0.40 | $ | 1.14 | $ | 1.05 | |||||||||||||||
| Weighted average common shares outstanding, diluted | 171,941 | 180,528 | 173,848 | 181,286 | |||||||||||||||||||
(1) Restructuring, acquisition, integration and other for the nine months ended September 30, 2023 includes the Amedisys merger termination fee, net of merger-related expenses
(2) Tax adjustments for the three and nine months ended September 30, 2024 and 2023 includes the estimated income tax effect on non-GAAP adjustments based on the effective tax rate